Eli Lilly stock surged over 2% to $1011 per share, following Citi's target price increase to $1,500 from $1,250, suggesting a potential upside of more than 50%. Citigroup has maintained its 'Buy' rating for Eli Lilly. Additionally, Morgan Stanley raised the price target for Eli Lilly shares from $1090.00 to $1171.00 and maintained its overweight rating, reflecting confidence in the company's future performance.